PD-1 related transcriptome profile and clinical outcome in diffuse gliomas

References

• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4. doi:10.1126/scitranslmed.aad7118. PMID:26936508.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56-61. doi:10.1126/science.aaa8172.
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. The New England journal of medicine. 2008;359:492-507. doi:10.1056/NEJMra0708126.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005;352:987-96. doi:10.1056/NEJMoa043330.
   PubMed Web of Science ®Google Scholar
• Tambur AR, Roitberg B. Immunology of the central nervous system. Neurol Res. 2005;27:675-8. doi:10.1179/016164105X49544.
   PubMed Web of Science ®Google Scholar
• Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337-341. doi:10.1038/nature14432. PMID:26030524
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 2012;1:1223-5. doi:10.4161/onci.21335.
   PubMed Web of Science ®Google Scholar
• Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. Journal of hematology & oncology. 2013;6:74. doi:10.1186/1756-8722-6-74.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews Cancer. 2012;12:252-64. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Bosco A, Millward MJ, Small M, Nowak AK, Lake RA. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nat Rev Drug Discov. 2017;16:264-272. doi:10.1038/nrd.2016.233. PMID:28057932
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-65. doi:10.1056/NEJMoa1200694.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-28. doi:10.1056/NEJMoa1501824.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122-33. doi:10.1056/NEJMoa1302369.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006-17. doi:10.1056/NEJMoa1414428.
   PubMed Web of Science ®Google Scholar
• Bao ZS, Chen HM, Yang MY, Zhang CB, Yu K, Ye WL, Hu BQ, Yan W, Zhang W, Akers J, et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res. 2014;24:1765-73. doi:10.1101/gr.165126.113.
   PubMed Web of Science ®Google Scholar
• Yan W, Zhang W, You G, Bao Z, Wang Y, Liu Y, Kang C, You Y, Wang L, Jiang T. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One. 2012;7:e30339. doi:10.1371/journal.pone.0030339. PMID:22291938.
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218. doi:10.1186/s13059-016-1070-5. PMID:27765066.
   PubMed Web of Science ®Google Scholar
• Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009;11:R15. doi:10.1186/bcr2234. PMID:19272155.
   PubMed Web of Science ®Google Scholar
• Garber ST, Hashimoto Y, Weathers S-P, Xiu J, Gatalica Z, Verhaak RGW, Zhou S, Fuller GN, Khasraw M, de Groot J, et al. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro-Oncology. 2016;18:1357-66. doi:10.1093/neuonc/now132.
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110. doi:10.1016/j.ccr.2009.12.020.
   PubMed Web of Science ®Google Scholar
• Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157-73. doi:10.1016/j.ccr.2006.02.019.
   PubMed Web of Science ®Google Scholar
• Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell. 2013;24:331-46. doi:10.1016/j.ccr.2013.08.001.
   PubMed Web of Science ®Google Scholar
• Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M, Heimberger AB. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res. 2013;1:112-22. doi:10.1158/2326-6066.CIR-13-0028.
   PubMed Web of Science ®Google Scholar
• Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5:200ra116. doi:10.1126/scitranslmed.3006504.
   PubMed Web of Science ®Google Scholar
• Donkor MK, Sarkar A, Savage PA, Franklin RA, Johnson LK, Jungbluth AA, Allison JP, Li MO. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-beta1 cytokine. Immunity. 2011;35:123-34. doi:10.1016/j.immuni.2011.04.019.
   PubMed Web of Science ®Google Scholar
• Stephen TL, Payne KK, Chaurio RA, Allegrezza MJ, Zhu H, Perez-Sanz J, Perales-Puchalt A, Nguyen JM, Vara-Ailor AE, Eruslanov EB, et al. SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. Immunity. 2017;46:51-64. doi:10.1016/j.immuni.2016.12.015.
   PubMed Web of Science ®Google Scholar
• van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67:2-17.
   PubMed Web of Science ®Google Scholar
• Jung K, Choi I. Emerging Co-signaling Networks in T Cell Immune Regulation. Immune Netw. 2013;13:184-93. doi:10.4110/in.2013.13.5.184.
   PubMedGoogle Scholar
• Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117:1147-54. doi:10.1172/JCI31178.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Eggermont A, Sautes-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L, et al. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 2014;3:e957994. doi:10.4161/21624011.2014.957994. PMID:25941578.
   PubMed Web of Science ®Google Scholar
• Dempke WC, Fenchel K, Uciechowski P, Dale SP. Second-and third-generation drugs for immuno-oncology treatment—The more the better? European Journal of Cancer. 2017;74:55-72. doi:10.1016/j.ejca.2017.01.001.
   PubMed Web of Science ®Google Scholar
• Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373:1270-1. doi:10.1056/NEJMoa1504030.
   PubMed Web of Science ®Google Scholar